首頁 > 市場調查報告書 > 食物/飲料

機能性食品

市場調查報告書

商品編碼

1512669

全球益生菌 IBS 補充劑市場 - 2024-2031

Global Probiotic IBS Supplements Market - 2024-2031

出版日期: 2024年07月10日 | 出版商:

DataM Intelligence | 英文 235 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

概述

2023年，全球益生菌IBS補充劑市場達到2,912萬美元，預計2031年將達到4,879萬美元，2024-2031年預測期間複合年成長率為7.65%。

益生菌已顯示出緩解腸躁症症狀的潛力。美國胃腸病學會的一項統合分析發現，益生菌可能有助於改善腸躁症的整體症狀，包括腹脹和腸胃氣脹。消費者對腸道健康益處的認知不斷提高，消化系統疾病的發生率不斷上升，以及對益生菌對消化以外的潛在健康影響的不斷探索，推動了益生菌市場的擴張。

消費者越來越認知到益生菌對消化系統健康的潛在益處，包括控制腸躁症的症狀。隨著越來越多的人熟悉益生菌及其在促進腸道健康中的作用，對益生菌補充劑的需求，特別是與腸躁症等疾病相關的需求增加，推動了全球市場的成長。

北美主導全球益生菌腸躁症補充劑市場。益生菌補充劑在北美各個方面的大量應用正在積極促進該地區的市場擴張。根據國際食品資訊理事會 2022 年 4 月進行的食品與健康調查，約 33% 的美國受訪者努力在飲食中添加益生菌，其中 60% 的受訪者希望每天都這樣做。

動力學

腸躁症的盛行率不斷增加

全球腸躁症（IBS）發生率的上升是益生菌補充劑市場的重要動力。據國際胃腸道疾病基金會稱，全球估計有 5-10% 的人口患有 IBS。同樣，2023 年 9 月，Cedars-Sinai 研究人員的一項新研究結果顯示，腸躁症比之前認為的更為普遍。大約 20% 到 40% 的胃腸病專家就診是由於腸躁症 (IBS) 症狀。

隨著越來越多的人被診斷出患有腸躁症，對有效管理和緩解方案的需求不斷成長，益生菌因其對腸道健康的益處而成為首選之一。許多人喜歡自然和整體的方法來管理腸躁症等健康狀況。益生菌由促進健康腸道微生物群的有益細菌組成，與人們對自然療法的偏好非常一致。

益生菌的使用不斷增加

益生菌以其透過維持平衡的腸道微生物群和支持免疫功能來促進消化健康的潛力而聞名。消費者對益生菌益處的認知不斷提高，推動了益生菌在包括消化健康在內的各個應用領域的廣泛消費。

國際食品資訊理事會2021 年進行的一項調查顯示，51% 的美國人將益生菌納入飲食中以促進腸道健康，33% 的美國人將益生菌用於增強免疫功能，38% 的美國人將益生菌用於整體健康和保健目的， 13% 的人表示食用益生菌是為了支持情緒健康。

益生菌被認為有助於恢復腸道細菌的平衡，而腸躁症患者的腸道細菌平衡可能會被破壞。一些研究表明，某些益生菌菌株可能透過調節腸道微生物群組成、減少發炎和改善腸道屏障功能來幫助緩解 IBS 症狀。據 NIH 稱，許多薈萃分析評估了益生菌對 IBS 患者的影響，大多數得出的結論是益生菌在緩解症狀方面具有積極作用。

藥物治療的競爭

雖然益生菌補充劑提供了一種自然而全面的方法來控制腸躁症症狀，但它們面臨藥物治療的競爭。解痙藥、瀉藥和抗憂鬱藥等治療藥物通常用於治療 IBS。與益生菌補充劑相比，藥物治療提供了不同的症狀管理方法。

藥物治療通常針對特定症狀或疾病的潛在機制。它們可以更立即地緩解腹痛、腹脹和排便不規律等症狀。此外，它們通常由醫療保健專業人員開處方，為尋求症狀緩解的患者提供一定程度的保證和指導。

Probiotics have shown a potential to relieve irritable bowel syndrome symptoms. An American College of Gastroenterology meta-analysis found that probiotics may help improve overall IBS symptoms, including bloating and flatulence. The expansion of the probiotics market is propelled by heightened consumer awareness of the benefits to gut health, a growing incidence of digestive disorders, and continuous exploration of probiotics' potential health impacts extending beyond digestion.

There's a heightened awareness among consumers regarding the potential benefits of probiotics for digestive health, including managing symptoms of IBS. As more people become familiar with probiotics and their role in promoting gut health, the demand for probiotic supplements, specifically related to conditions like IBS, increases driving the market growth worldwide.

North America dominates the global probiotic IBS supplements market. The high use of probiotic supplements in various aspects of application in North America is positively improving the market expansion in this region. According to the Food and Health Survey conducted by the International Food Information Council in April 2022, around 33% of respondents in the United States make an effort to include probiotics in their diets, with 60% aiming to do so daily.

Dynamics

Increasing Prevalence of Irritable Bowel Syndrome

The rising incidence of IBS worldwide is a significant driver for the probiotic supplements market. According to the International Foundation for Gastrointestinal Disorders, the worldwide estimation of IBS is reported to be 5-10% of the population. Similarly, in September 2023, results from a new study by Cedars-Sinai investigators revealed that irritable bowel syndrome is more prevalent than previously thought. Approximately 20 to 40% of all visits to gastroenterologists are due to IBS symptoms.

As more individuals are diagnosed with IBS, there's a growing demand for effective management and relief options, with probiotics being one of the preferred choices due to their perceived benefits in gut health. Many individuals prefer natural and holistic approaches to managing health conditions like IBS. Probiotics, which consist of beneficial bacteria that promote a healthy gut microbiota, align well with this preference for natural remedies.

Rising Use of Probiotics

Probiotics are known for their potential to promote digestive health by maintaining a balanced intestinal microbiota and supporting immune function. Increasing consumer awareness regarding the benefits of probiotics is driving the wide consumption of probiotics in various application sectors including digestive health.

In a 2021 survey conducted by the International Food Information Council, findings indicated that 51% of Americans incorporate probiotics into their diets to promote gut health, 33% use them to bolster immune function, 38% integrate probiotics for overall health and wellness purposes, and 13% reported consuming probiotics to support emotional well-being.

Probiotics are believed to help restore the balance of gut bacteria, which can be disrupted in individuals with IBS. Some studies suggest that certain probiotic strains may help relieve IBS symptoms by modulating gut microbiota composition, reducing inflammation and improving intestinal barrier function. According to NIH, numerous meta-analyses have evaluated the impact of probiotics on individuals with IBS with the majority concluding that probiotics offer a positive effect in alleviating symptoms.

Competition from Pharmaceutical Treatments

While probiotic supplements offer a natural and holistic approach to managing IBS symptoms, they face competition from pharmaceutical treatments. The treatments such as antispasmodics, laxatives and antidepressants, are commonly prescribed for IBS management. Pharmaceutical treatments offer a different approach to symptom management compared to probiotic supplements.

Pharmaceutical treatments typically target specific symptoms or underlying mechanisms of the condition. They provide more immediate relief of symptoms such as abdominal pain, bloating, and irregular bowel movements. In addition, they are often prescribed by healthcare professionals, providing a level of assurance and guidance for patients seeking symptom relief.

Segment Analysis

The global probiotic IBS supplements market is segmented based on strain, form, distribution channel, end-user and region.

Potential Benefits of Bifidobacterium

The global probiotic IBS supplements market is segmented based on strain into lactobacillus, bifidobacterium and others. The bifidobacterium segment accounted for the largest share of the global market. Bifidobacterium strains, such as Bifidobacterium infantis and Bifidobacterium longum, have been extensively studied for their potential benefits in managing symptoms of IBS.

Clinical trials and research studies have consistently shown positive outcomes, including improved abdominal pain, bloating and bowel habits. According to Harvard studies, Bifidobacterium bifidum MIMBb75, probiotic strain, has demonstrated strong adherence to intestinal cells, suggesting it may effectively modify the gut microbiota and enhance the intestinal barrier.

Clinical trials published in Alimentary Pharmacology & Therapeutics have shown that daily supplementation with Bifidobacterium bifidum MIMBb75 significantly improved overall IBS symptoms, as well as individual symptoms like abdominal pain, bloating and fecal urgency. Also, recent research has indicated that even heat-inactivated Bifidobacterium bifidum MIMBb75 can relieve IBS symptoms.

Geographical Penetration

High Prevalence of Irritable Bowel Syndrome in North America

North America dominates the global probiotic IBS supplements market. North America has a relatively high prevalence of irritable bowel syndrome, with millions of individuals affected by this condition. The International Foundation for Gastrointestinal Disorders recently reported that IBS affects between 25 and 45 million people in United States. About 2 in 3 IBS sufferers are female, while 1 in 3 IBS sufferers are male.

The large patient population creates a significant market opportunity for products targeting IBS management. With a strong culture of health and wellness in North America, many consumers actively seek natural and holistic approaches to managing health conditions like IBS. Probiotic supplements are perceived as safe and effective options for promoting digestive health and alleviating symptoms of IBS, fitting well with the preferences of health-conscious consumers in the region.

Competitive Landscape

The major global players in the market include The Good Bug, Zeroharm Sciences Private Limited, Menoveda Life Sciences Private Limited, Unique Biotech Limited, Projoy Pvt Ltd, Pure NSM - Nutritional Supplement Manufacturers, Inc., Nature's Bounty, Hyperbiotics, Advanced Vital Enzymes Private Ltd and Wren Laboratories Ltd.

COVID-19 Impact Analysis

The COVID-19 had a moderate impact on the global probiotic IBS supplements market. The probiotic supplements market, like many other industries, has been impacted by disruptions in global supply chains caused by the pandemic. Restrictions on travel, closures of manufacturing facilities and logistical challenges have led to delays in production and distribution, affecting the availability of probiotic products in some regions.

The pandemic has heightened awareness about the importance of maintaining a healthy immune system. Probiotics, known for their role in gut health, have gained attention for their potential immune-supporting properties. The greater demand for products perceived to promote overall health positively impacted the probiotic supplements market. Individuals with IBS are motivated to explore natural remedies like probiotics to support their immune and digestive health.

By Strain

Lactobacillus
Bifidobacterium
Other

By Form

Tablet
Capsules
Liquid
Powder
Others

By Distribution Channel

Supermarkets/Hypermarkets
Pharmacy/Health Stores
Online Stores
Other

By End-User

Infant
Children
Adults
Seniors

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- UK
- France
- Italy
- Russia
- Rest of Europe
South America
- Brazil
- Argentina
- Rest of South America
Asia-Pacific
- China
- India
- Japan
- Australia
- Rest of Asia-Pacific
Middle East and Africa

Key Developments

In August 2023, Hyperbiotics introduced PRO-IBS Support. This innovative product features a dual-action synergistic blend of Lactiplantibacillus plantarum 299v and highly bioavailable Boswellia serrata extract. The formulation aims to effectively alleviate gut discomfort and dysfunction in individuals with IBS.
In August 2022, researchers at the University of Nottingham secured £1.8 million in funding for a three-year project to explore the potential benefits of cellulose-based food supplements for individuals suffering from Irritable Bowel Syndrome, focusing on colon fermentation.

Why Purchase the Report?

To visualize the global probiotic IBS supplements market segmentation based on strain, form, distribution channel, end-user and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of probiotic IBS supplements market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.

The global probiotic IBS supplements market report would provide approximately 70 tables, 76 figures and 235 pages.

Target Audience 2024

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Strain
3.2. Snippet by Form
3.3. Snippet by Distribution Channel
3.4. Snippet by End-User
3.5. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing Prevalence of Irritable Bowel Syndrome
  - 4.1.1.2. Rising Use of Probiotics
- 4.1.2. Restraints
  - 4.1.2.1. Competition from Pharmaceutical Treatments
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. DMI Opinion

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID
- 6.1.2. Scenario During COVID
- 6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Strain

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Strain
- 7.1.2. Market Attractiveness Index, By Strain
7.2. Lactobacillus
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Bifidobacterium
7.4. Other

8. By Form

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
- 8.1.2. Market Attractiveness Index, By Form
8.2. Tablet
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Capsules
8.4. Liquid
8.5. Powder
8.6. Others

9. By Distribution Channel

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Supermarkets/Hypermarkets
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Pharmacy/Health Stores
9.4. Online Stores
9.5. Other

10. By End-User

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.1.2. Market Attractiveness Index, By End-User
10.2. Infants
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Children
10.4. Adults
10.5. Seniors

11. By Region

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 11.1.2. Market Attractiveness Index, By Region
11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Strain
- 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
- 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.2.7.1. U.S.
  - 11.2.7.2. Canada
  - 11.2.7.3. Mexico
11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Strain
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
- 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.3.7.1. Germany
  - 11.3.7.2. U.K.
  - 11.3.7.3. France
  - 11.3.7.4. Italy
  - 11.3.7.5. Spain
  - 11.3.7.6. Rest of Europe
11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Strain
- 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
- 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.4.7.1. Brazil
  - 11.4.7.2. Argentina
  - 11.4.7.3. Rest of South America
11.5. Asia-Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Strain
- 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
- 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.5.7.1. China
  - 11.5.7.2. India
  - 11.5.7.3. Japan
  - 11.5.7.4. Australia
  - 11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Strain
- 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
- 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis

13. Company Profiles

13.1. The Good Bug
- 13.1.1. Company Overview
- 13.1.2. Product Portfolio and Description
- 13.1.3. Financial Overview
- 13.1.4. Key Developments
13.2. Zeroharm Sciences Private Limited
13.3. Menoveda Life Sciences Private Limited
13.4. Unique Biotech Limited
13.5. Projoy Pvt Ltd
13.6. Pure NSM - Nutritional Supplement Manufacturers, Inc.
13.7. Nature's Bounty
13.8. Hyperbiotics
13.9. Advanced Vital Enzymes Private Ltd
13.10. Wren Laboratories Ltd

LIST NOT EXHAUSTIVE